April 17, 2018 Acad, Gov/Utilities

FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors

Basel, 17 April 2018 FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior factor VIII prophylaxis in an intra-patient comparison Roche (SIX: RO, ROG;... Read more

April 17, 2018 Acad, Gov/Utilities

FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors

Basel, 17 April 2018 FDA grants Breakthrough Therapy Designation for Roche’s Hemlibra in haemophilia A without inhibitors Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior factor VIII prophylaxis in an intra-patient comparison Roche (SIX: RO, ROG;... Read more

April 16, 2018 Atomic Spectroscopy Licensing, IP, and Legal PR/Corporate Product Launch

Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline

Basel, 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer’s... Read more

April 16, 2018 Atomic Spectroscopy Licensing, IP, and Legal PR/Corporate Product Launch

Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline

Basel, 16 April 2018 Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline Breadth of data will reinforce efficacy and safety of OCREVUS in relapsing and primary progressive multiple sclerosis and demonstrate its benefits in slowing disability progression, including new cognitive and biomarker results Important research in Alzheimer’s... Read more

April 14, 2018 Atomic Spectroscopy PR/Corporate

Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting

Basel, 14 April 2018 Roche to present data on TECENTRIQ (Atezolizumab) and data from across its cancer immunotherapy portfolio at the 2018 American Association of Cancer Research (AACR) Annual Meeting Data highlight commitment to personalised cancer immunotherapy combinations that stimulate deep anti-cancer immune responses Updated data from the Phase III IMpower150 study shows clinically meaningful... Read more

April 6, 2018 M&A, Partnerships

Roche completes acquisition of Flatiron Health

Basel, 06 April 2018 Roche completes acquisition of Flatiron Health Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as... Read more

April 6, 2018 M&A, Partnerships

Roche completes acquisition of Flatiron Health

Basel, 06 April 2018 Roche completes acquisition of Flatiron Health Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as... Read more

April 6, 2018 M&A, Partnerships

Roche completes acquisition of Flatiron Health

Basel, 06 April 2018 Roche completes acquisition of Flatiron Health Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has completed the acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York City, US. Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as... Read more